Jon P. Stonehouse - 27 Feb 2026 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Director
Issuer ticker: BCRX
Reported as of: 27 Feb 2026
Net transaction value: -$1,654,809
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:34:13 UTC
Prior SEC filing: 23 Dec 2025
Next SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes, by power of attorney

Key filing fact

Jon P. Stonehouse filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 03 Mar 2026.

Key facts

This page summarizes Jon P. Stonehouse's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 16:34.

Change

Previous filing in this sequence was filed on 23 Dec 2025.
Current net transaction value: -$1,654,809.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001385496 Primary reporting owner

Stonehouse Jon P

Relationship: Director
Address: 4505 EMPEROR BLVD., SUITE 200, DURHAM
Signature: /s/ Alane P. Barnes, by power of attorney
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX transaction

Common Stock

Award

Transaction value: $3,684
Shares: +421
Change %: +0.03%
Price: $8.75
Shares after: 1,323,850
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1

BCRX transaction

Common Stock

Options Exercise

Transaction value: $985,304
Shares: +305,995
Change %: +23%
Price: $3.22
Shares after: 1,629,845
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2

BCRX transaction

Common Stock

Disposed to Issuer

Transaction value: $2,643,797
Shares: -305,995
Change %: -19%
Price: $8.64
Shares after: 1,323,850
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2, F3

BCRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,000
Date: 27 Feb 2026
Ownership: By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust

BCRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,000
Date: 27 Feb 2026
Ownership: By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCRX transaction Derivative

Emp. Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -305,995
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 305,995
Exercise price: $3.22
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375.

Footnote F2

This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Footnote F3

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.